A novel plasma lncRNA ENST00000416361 is upregulated in coronary artery disease and is related to inflammation and lipid metabolism

Abstract

coronary artery disease (cad) is a serious threat to human health and a major cause of mortality worldwide. long noncoding rnas (lncrnas) affect the occurrence and development of cad via the regulation of cell proliferation and apoptosis, inflammatory responses and lipid metabolism. Screening methods and therapeutic strategies for cad have been extensively studied. The present study analyzed clinical indexes of 187 patients with CAD and 150 healthy subjects. The data showed significant differences in diabetes mellitus, hypertension, high-density lipoprotein level and smoking history between the CAD group and the control group. A series of differentially expressed lncRNAs were detected in the plasma samples of three patients with CAD by high-throughput sequencing. reverse transcription-quantitative (rT-q)Pcr data revealed that the expression level of the novel lncRNA enST00000416361 was ~2.3-fold higher in the plasma of 50 patients with CAD compared with the 50 control subjects. receiver operating characteristic (roc) curves were generated, and the area under the roc curve was 0.7902. Knockdown of ENST00000416361 in human umbilical vein endothelial cells markedly downregulated interleukin-6 and tumor necrosis factor-α levels. In addition, sterol regulatory element binding transcription factor (SreBP)1 and SreBP2 were upregulated in patients with cad, and they were positively correlated with the expression of ENST00000416361. RT-qPCR further demonstrated that knockdown of enST00000416361 led to the downregulation of SreBP1 and SreBP2. overall, the novel lncRNA ENST00000416361 may be associated with CAD-induced inflammation and lipid metabolism, and it may serve as a potential biomarker for CAD.

Long noncoding RNA uc003pxg.1 regulates endothelial cell proliferation and migration via miR‑25‑5p in coronary artery disease

“…The lncRNA uc003pxg.1 was discovered by lncRNA-seq high-throughput sequencing performed in our previous study ( 22 ). In the present study, the relative expression levels of uc003pxg.1 in PBMCs from 80 patients with CAD and 80 controls were determined by RT-qPCR.…”

“…In our previous study, a number of lncRNAs were identified as differentially expressed in patients with CAD compared with healthy controls through high-throughput sequencing ( 22 ). Among these lncRNAs, the functional lncRNA uc003pxg.1 was demonstrated to function in cell proliferation and migration through high-content analysis in the present study.…”

“…The original sequencing data of lncRNA-seq from our previous study ( 22 ) and miRNA-seq from the current study were uploaded to the GEO database of NCBI (accession nos. lncRNA-seq, GSE171551; https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE171551 ; miRNA-seq, GSE171715; https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE171715 ).…”

“…The original sequencing data of lncRNA-seq from our previous study (22) and miRNA-seq from the current study were uploaded to the gEO database of NcBI (accession nos. lncRNA-seq, gSE171551; https://www.ncbi.…”

“…In our previous study, a previously unreported lncRNA uc003pxg.1 was identified ( 22 ); the genomic location and sequence of uc003pxg.1 are presented in Data S1 . The aim of the present study was to determine whether the expression levels of uc003pxg.1 differed in peripheral blood mononuclear cells (PBMCs) isolated from patients with CAD and healthy control subjects, and to evaluate the interactions between miRNAs and uc003pxg.1 in human umbilical vein endothelial cells (HUVECs).…”